14 min

Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments Adis Journal Podcasts

    • Life Sciences

Dr. Massimo Breccia from the Department of Translational and Precision Medicine at the University of Rome joins us to talk through the top highlights of the chronic myeloid leukemia data from the 2021 American Society of Hematology Conference. Here he gives specific focus to patient unmet needs and later-line therapies for the disease.
This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link. All conflicts of interest can be found online.
This podcast is intended for medical professionals only.
This podcast has been developed through an educational grant from Novartis. The authors were selected by the journal, and the content of the podcast was developed independently by the authors and the journal Editors. The Rapid Service and Open Access Fees were funded by an unrestricted educational grant from Novartis.
Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
 

Dr. Massimo Breccia from the Department of Translational and Precision Medicine at the University of Rome joins us to talk through the top highlights of the chronic myeloid leukemia data from the 2021 American Society of Hematology Conference. Here he gives specific focus to patient unmet needs and later-line therapies for the disease.
This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link. All conflicts of interest can be found online.
This podcast is intended for medical professionals only.
This podcast has been developed through an educational grant from Novartis. The authors were selected by the journal, and the content of the podcast was developed independently by the authors and the journal Editors. The Rapid Service and Open Access Fees were funded by an unrestricted educational grant from Novartis.
Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
 

14 min